Targeting the PDGF signaling pathway in the treatment of non-malignant diseases

Journal of Neuroimmune Pharmacology

Volumn 9, Issue 2, 2014, Pages 69-79

  Heldin, Carl Henrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Artherosclerosis; Fibrotic conditions; Inhibitor; Kinase; PDGF; Receptor; Treatment

Indexed keywords

ALPHA RECEPTOR TYROSINE KINASE RECEPTOR; APTAMER; BETA TYROSINE KINASE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ISOPROTEIN; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ATHEROSCLEROSIS; DRUG TARGETING; EMBRYO DEVELOPMENT; FIBROSIS; HOMEOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; FIBROSIS; HUMANS; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84896544087     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9484-2     Document Type: Review

References (156)

1. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201(6):925-935 (Pubitemid 40524462)
2. Abrams MB, Nilsson I, Lewandowski SA, Kjell J, Codeluppi S, Olson L, Eriksson U (2012) Imatinib enhances functional outcome after spinal cord injury. PLoS One 7(6):e38760
3. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, Zwerina J, Gay S, Schett G, Distler O et al (2008) Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 22(7):2214-2222 (Pubitemid 351948641)
4. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH (2009) Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 60(1):219-224
5. Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, Groeneveld AB, Vonk Noordegraaf A, van Hinsbergh VW, van Nieuw Amerongen GP (2012) Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 126(23):2728-2738
6. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276-1312 (Pubitemid 351717519)
7. Antoniu SA (2012) Targeting PDGF pathway in pulmonary arterial hypertension. Expert Opin Ther Targets 16(11):1055-1063
8. Arcot SS, Lipke DW, Gillespie MN, Olson JW (1993) Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 46(6):1086-1091 (Pubitemid 23280552)
9. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K et al (2010) Pericytes regulate the blood-brain barrier. Nature 468(7323):557-561
10. Balada E, Simeon-Aznar CP, Ordi-Ros J, Rosa-Leyva M, Selva-O'Callaghan A, Pardos-Gea J, Fonollosa-Pla V, Vilardell-Tarres M (2008) Anti-PDGFR-α antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 67(7):1027-1029 (Pubitemid 351956668)
11. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284(5):L826-L833 (Pubitemid 36459029)
12. Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R et al (1998) PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97(19):1960-1969 (Pubitemid 28222191)
13. Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas OA, Linkesch W (2002) Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99(1):381-383
14. Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15(4):255-273
15. Boor P, Konieczny A, Villa L, Kunter U, van Roeyen CR, LaRochelle WJ, Smithson G, Arrol S, Ostendorf T, Floege J (2007) PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 22(5):1323-1331 (Pubitemid 47072219)
16. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R (2007) Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 46(6):1064-1074 (Pubitemid 46669736)
17. Boström H, Willetts K, Pekny M, Levéen P, Lindahl P, Hedstrand H, Pekna M, Hellström M, Gebre-Medhin S, Schalling M et al (1996) PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85(6):863-873 (Pubitemid 26192137)
18. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J (2003) LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300(5617):329-332 (Pubitemid 36433724)
19. Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H (2004) Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 101(2):332-336 (Pubitemid 38890837)
20. Cai Y, Han M, Luo L, Song W, Zhou X (1996) Increased expression of PDGF and c-myc genes in lungs and pulmonary arteries of pulmonary hypertensive rats induced by hypoxia. Chin Med Sci J 11(3):152-156
21. Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, Betsholtz C, Richardson WD (1998) Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 20(5):869-882 (Pubitemid 28247393)
22. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS et al (2005) Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 102(9):3389-3394 (Pubitemid 40328055)
23. Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA (2009) Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 53(1):129-132
24. Chen H, Gu X, Liu Y, Wang J, Wirt SE, Bottino R, Schorle H, Sage J, Kim SK (2011a) PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature 478(7369):349-355
25. Chen YT, Chang FC, Wu CF, Chou YH, Hsu HL, Chiang WC, Shen J, Chen YM, Wu KD, Tsai TJ et al (2011b) Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 80(11):1170-1181
26. Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL et al (2009) Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60(2):584-591
27. Classen J-F, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikström G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi J-P et al (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60(4):1137-1144
28. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, Schirmacher P, Biesterfeld S, Galle PR, Lohse AWet al (2006) Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45(3):419-428 (Pubitemid 44142114)
29. Dahal BK, Heuchel R, Pullamsetti SS, Wilhelm J, Ghofrani HA, Weissmann N, Seeger W, Grimminger F, Schermuly RT (2011) Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β. Pulm Circ 1(2):259-268
30. Dai Y (2010) Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature. Expert Opin Ther Pat 20(7):885-897
31. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR (2010) Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181(6):604-610
32. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640-2653 (Pubitemid 40446252)
33. Demetri GD (2011) Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 38(Suppl 1):S10-S19
34. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA (2003) Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9(10):1306-1312 (Pubitemid 37279855)
35. Ding H, Wu X, Bostrom H, Kim I, Wong N, Tsoi B, O'Rourke M, Koh GY, Soriano P, Betsholtz C et al (2004) A specific requirement for PDGF-C in palate formation and PDGFR-α signaling. Nat Genet 36(10):1111-1116 (Pubitemid 41184474)
36. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56(1):311-322 (Pubitemid 46106205)
37. Distler JH, Manger B, Spriewald BM, Schett G, Distler O (2008) Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 58(8):2538-2542
38. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031-1037 (Pubitemid 32267972)
39. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 38(1):218-220
40. Egawa-Tsuzuki T, Ohno M, Tanaka N, Takeuchi Y, Uramoto H, Faigle R, Funa K, Ishii Y, Sasahara M (2004) The PDGF B-chain is involved in the ontogenic susceptibility of the developing rat brain to NMDA toxicity. Exp Neurol 186(1):89-98 (Pubitemid 38229908)
41. Eitner F, Bucher E, van Roeyen C, Kunter U, Rong S, Seikrit C, Villa L, Boor P, Fredriksson L, Backstrom G et al (2008) PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 19(2):281-289 (Pubitemid 351240650)
42. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253:1129-1132 (Pubitemid 21917260)
43. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N (1999) Novel approach to specific growth factor inhibition in vivo. Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 154(1):169-179 (Pubitemid 29031624)
44. Floege J, Eitner F, Alpers CE (2008) A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19(1):12-23
45. Fredriksson L, Li H, Fieber C, Li X, Eriksson U (2004) Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23(19):3793-3802 (Pubitemid 39389710)
46. Fredriksson L, Nilsson I, Su EJ, Andrae J, Ding H, Betsholtz C, Eriksson U, Lawrence DA (2012) Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. Am J Pathol 180(3):1136-1144
47. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134(6):1655-1669
48. Gay S, Jones REJ, Huang GQ, Gay RE (1989) Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sisoncogene expression in scleroderma. J Invest Dermatol 92:301-303 (Pubitemid 19061278)
49. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161(6):1163-1177 (Pubitemid 36870177)
50. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F et al (2010) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 182(9):1171-1177
51. Giese NA, Marijianowski MMH, McCook O, Hancock A, Ramakrishnan V, Fretto LJ, Chen C, Kelly AB, Koziol JA, Wilcox JN et al (1999) The role of α and β platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. Arterioscler Thromb Vasc Biol 19(4):900-909 (Pubitemid 29177336)
52. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ (2001) PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59(4):1324-1332 (Pubitemid 32281220)
53. Gordon JK, Spiera RF (2010) Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol 22(6):690-695
54. Green LS, Jellinek D, Jenison R, Östman A, Heldin C-H, Janjic N (1996) Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35(45):14413-14424 (Pubitemid 26384438)
55. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685-1695
56. Hart CE, Kraiss LW, Vergel S, Gilbertson D, Kenagy R, Kirkman T, Crandall DL, Tickle S, Finney H, Yarranton G et al (1999) PDGF α receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99(4):564-569 (Pubitemid 29061874)
57. Hawthorne T, Giot L, Blake L, Kuang B, Gerwien R, Smithson G, Hahne W, Mansfield T, Starling GC, Pochart P et al (2008) A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther 46(5):236-244 (Pubitemid 351663160)
58. Heldin C-H, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283-1316 (Pubitemid 29473317)
59. Heldin C-H, Rubin K, Pietras K, Östman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4(10):806-813 (Pubitemid 39331152)
60. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T (2009) Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 157(2):258-270
61. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, Brummendorf TH, Klose H (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11:30
62. Hoch RV, Soriano P (2003) Roles of PDGF in animal development. Development 130(20):4769-4784 (Pubitemid 37321862)
63. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA, Grimminger F, Grunig E, Hassoun PM et al (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 127(10):1128-1138
64. Huang Q, Sun R (1997) Changes of PDGF-α and β receptor gene expression in hypoxic rat pulmonary vessels. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 19(6):470-473
65. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G et al (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11(3):554-559 (Pubitemid 28194842)
66. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS (2010) Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176(1):85-97
67. Hunzelmann N, Brinckmann J (2010) What are the new milestones in the pathogenesis of systemic sclerosis? Ann Rheum Dis 69(Suppl 1):i52-i56
68. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23(5):973-981 (Pubitemid 46202317)
69. Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG (2011) Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 117(4):c312-c319
70. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R (1992) Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175(5):1413-1416
71. Karlsson L, Lindahl P, Heath JK, Betsholtz C (2000) Abnormal gastrointestinal development in PDGF-A and PDGFR-α deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development 127(16):3457-3466
72. Katayose D, Ohe M, Yamauchi K, Ogata M, Shirato K, Fujita H, Shibahara S, Takishima T (1993) Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 264(2 Pt 1):L100-L106 (Pubitemid 23079462)
73. Kavian N, Servettaz A, Marut W, Nicco C, Chereau C, Weill B, Batteux F (2012) Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor beta in the skin of mice with sclerodermalike features and prevents the development of the disease. Arthritis Rheum 64(6):1990-2000
74. Keramati AR, Singh R, Lin A, Faramarzi S, Ye ZJ, Mane S, Tellides G, Lifton RP, Mani A (2011) Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 108(5):1914-1918
75. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908-916 (Pubitemid 44175142)
76. Kono SA, Heasley LE, Doebele RC, Camidge DR (2012) Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 12(2):107-123
77. Kurasawa K, Arai S, Owada T, Maezawa R, Kumano K, Fukuda T (2010) Autoantibodies against platelet-derived growth factor receptor α in patients with systemic lupus erythematosus. Mod Rheumatol 20(5):458-465
78. Lanner MC, Raper M, Pratt WM, Rhoades RA (2005) Heterotrimeric G proteins and the platelet-derived growth factor receptor-β contribute to hypoxic proliferation of smooth muscle cells. Am J Respir Cell Mol Biol 33(4):412-419 (Pubitemid 41416293)
79. Lazar J, Poonawalla T, Teng JM (2011) A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy. Pediatr Dermatol 28(2):172-175
80. Lei H, Rheaume MA, Kazlauskas A (2010) Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res 90(3):376-381
81. Lei H, Velez G, Kazlauskas A (2011) Pathological signaling via platelet-derived growth factor receptor α involves chronic activation of Akt and suppression of p53. Mol Cell Biol 31(9):1788-1799
82. Leppänen O, Miyazawa K, Bäckström G, Pietras K, Sjöblom T, Heldin C-H, Östman A (2000) Predimerization of recombinant platelet-derived growth factor receptor extracellular domains increases antagonistic potency. Biochemistry 39(9):2370-2375
83. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8(16):1875-1887 (Pubitemid 24273888)
84. Lewis CD, Olson NE, Raines EW, Reidy MA, Jackson CL (2001) Modulation of smooth muscle proliferation in rat carotid artery by platelet-derived mediators and fibroblast growth factor-2. Platelets 12(6):352-358 (Pubitemid 32896892)
85. Li M, Abdollahi A, Grone HJ, Lipson KE, Belka C, Huber PE (2009) Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol 4:66
86. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (2011) Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 10(10):590-594
87. Liao CH, Akazawa H, Tamagawa M, Ito K, Yasuda N, Kudo Y, Yamamoto R, Ozasa Y, Fujimoto M, Wang P et al (2010) Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest 120(1):242-253
88. Lin SL, Kisseleva T, Brenner DA, Duffield JS (2008) Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173(6):1617-1627
89. Lindahl P, Johansson BR, Levéen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242-245 (Pubitemid 27446080)
90. Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, Lam RW, Zhang GC, Zhang H, Ye T (2011) Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 55(3):612-625
91. Llanos L, Bellot P, Zapater P, Perez-Mateo M, Such J (2009) Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib. Am J Gastroenterol 104(1):257-258
92. Loizos N, Lariccia L,Weiner J, Griffith H, Boin F, Hummers L,Wigley F, Kussie P (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60(4):1145-1151
93. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658-6661 (Pubitemid 40053752)
94. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM (1995) Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22(10):1876-1883
95. Ma Q, Huang B, Khatibi N, Rolland W 2nd, Suzuki H, Zhang JH, Tang J (2011) PDGFR-α inhibition preserves blood-brain barrier after intracerebral hemorrhage. Ann Neurol 70(6):920-931
96. Maeda Y, Hirano K, Hirano M, Kikkawa Y, Kameda K, Sasaki T, Kanaide H (2009) Enhanced contractile response of the basilar artery to platelet-derived growth factor in subarachnoid hemorrhage. Stroke 40(2):591-596
97. Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315(5816):1278-1282 (Pubitemid 46364265)
98. Martin IV, Borkham-Kamphorst E, Zok S, van Roeyen CR, Eriksson U, Boor P, Hittatiya K, Fischer HP, Wasmuth HE, Weiskirchen R et al (2013) Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am J Pathol 182(1):107-117
99. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43(12):967-968
100. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, Michel BA, Gay S, Distler JH, Distler O (2012) Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 71(8):1382-1387
101. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49(4):1245-1256
102. Nguyen PT, Nakamura T, Hori E, Urakawa S, Uwano T, Zhao J, Li R, Bac ND, Hamashima T, Ishii Y et al (2011) Cognitive and socioemotional deficits in platelet-derived growth factor receptor-β gene knockout mice. PLoS One 6(3):e18004
103. Ogawa S, Ochi T, Shimada H, Inagaki K, Fujita I, Nii A, Moffat MA, Katragadda M, Violand BN, Arch RH et al (2010) Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res 40(11):1128-1141
104. Olson LE, Soriano P (2011) PDGFRβ signaling regulates mural cell plasticity and inhibits fat development. Dev Cell 20(6):815-826
105. Ostendorf T, Eitner F, Floege J (2012) The PDGF family in renal fibrosis. Pediatr Nephrol 27(7):1041-1050
106. Östman A, Heldin C-H (2013) Platelet-derived growth factor. In: Gelmann E, Sawers C, Rauscher F III (eds) Molecular oncology: Causes of cancer and targets for treatment. Cambridge University Press, Cambridge, in press
107. Patterson KC, Weissmann A, Ahmadi T, Farber HW (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145(2):152-153 (Pubitemid 46780594)
108. Peng F, Yao H, Bai X, Zhu X, Reiner BC, Beazely M, Funa K, Xiong H, Buch S (2010) Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1. J Biol Chem 285(28):21615-21624
109. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O et al (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178(1):81-88 (Pubitemid 351919196)
110. Pietras K, Sjöblom T, Rubin K, Heldin C-H, Östman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439-443 (Pubitemid 38340290)
111. Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M (2012) The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study. Aliment Pharmacol Ther 35(1):83-91
112. Pontén A, Li X, Thorén P, Aase K, Sjöblom T, Östman A, Eriksson U (2003) Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol 163(2):673-682 (Pubitemid 36909428)
113. Pontén A, Folestad EB, Pietras K, Eriksson U (2005) Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res 97(10):1036-1045 (Pubitemid 41668917)
114. Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA et al (2012) Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 32(6):1354-1365
115. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908-3914 (Pubitemid 47477268)
116. Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15(4):237-254
117. Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, Peck-Radosavljevic M (2009) Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 51(5):865-873
118. Rhee CK, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim YK, Kim KH, Kim TJ, Kim JW (2011) Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 82(3):273-287
119. Rice AB, Moomaw CR, Morgan DL, Bonner JC (1999) Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 155(1):213-221 (Pubitemid 29318719)
120. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365(12):1079-1087
121. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF (1992) Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23-25
122. Rodríguez-González R, Blanco M, Rodríguez- Yáñez M, Moldes O, Castillo J, Sobrino T (2013) Platelet derived growth factor-CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator. Atherosclerosis 226(1):165-171
123. Rodt SÅ, Åhlén K, Berg A, Rubin K, Reed RK (1996) A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 495(Pt 1):193-200 (Pubitemid 26288464)
124. Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, Nishikawa S, Nishikawa SI, Kita T (2001) Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103(24):2955-2960 (Pubitemid 32578134)
125. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115(10):2811-2821 (Pubitemid 41434408)
126. Schramm C, Schuch G, Lohse AW (2008) Sorafenib-induced liver failure. Am J Gastroenterol 103(8):2162-2163
127. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47(5):735-737 (Pubitemid 351619226)
128. Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D et al (2007) An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357(4):1142-1147 (Pubitemid 46693690)
129. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A et al (2009) Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 11(6):594-604
130. Shiba M, Suzuki H, Fujimoto M, Shimojo N, Imanaka-Yoshida K, Yoshida T, Kanamaru K, Matsushima S, Taki W (2012) Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats. Neurobiol Dis 46(1):172-179
131. Smith CL, Baek ST, Sung CY, Tallquist MD (2011) Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling. Circ Res 108(12):e15-e26
132. Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taieb A (2008) The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 216(2):109-117 (Pubitemid 351158574)
133. Soriano P (1994) Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Genes Dev 8(16):1888-1896
134. Soriano P (1997) The PDGFα receptor is required for neural crest cell development and for normal patterning of the somites. Development 124(14):2691-2700
135. Soroceanu L, Akhavan A, Cobbs CS (2008) Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455(7211):391-395
136. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61(8):736 (Pubitemid 44211786)
137. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK (2011) Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70(6):1003-1009
138. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M et al (2008) Activation of PDGF-CC by tissue
139. Svegliati Baroni S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354(25):2667-2676
140. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, Moroncini G, Bacigalupo A, Leoni P, Avvedimento EVet al (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110(1):237-241 (Pubitemid 47026840)
141. ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S (2009) Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 98(4):265-267
142. ten Freyhaus H, Dagnell M, Leuchs M, Vantler M, Berghausen EM, Caglayan E, Weissmann N, Dahal BK, Schermuly RT, Ostman A et al (2011) Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med 183(8):1092-1102
143. ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S (2012) Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 21(1):119-134
144. Thieringer F, Maass T, Czochra P, Klopcic B, Conrad I, Friebe D, Schirmacher P, Lohse AW, Blessing M, Galle PR et al (2008) Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene 423(1):23-28
145. Tuuminen R, Nykanen A, Keranen MA, Krebs R, Alitalo K, Koskinen PK, Lemstrom KB (2006) The effect of platelet-derived growth factor ligands in rat cardiac allograft vasculopathy and fibrosis. Transplant Proc 38(10):3271-3273 (Pubitemid 44908443)
146. Ustach CV, Kim HR (2005) Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25(14):6279-6288 (Pubitemid 40946575)
147. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, Kim HR (2010) A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 70(23):9631-9640
148. van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM (2008) Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58(8):2549-2552
149. van Roeyen CR, Eitner F, Boor P, Moeller MJ, Raffetseder U, Hanssen L, Bucher E, Villa L, Banas MC, Hudkins KL et al (2011) Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int 80(12):1292-1305
150. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H (2010) New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 53(1):132-144
151. Wen H, Lu Y, Yao H, Buch S (2011) Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability. PLoS One 6(6):e21707
152. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ (2004) Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 25(2):252-262 (Pubitemid 38344108)
153. Yamasaki Y, Miyoshi K, Oda N, Watanabe M, Miyake H, Chan J, Wang X, Sun L, Tang C, McMahon G et al (2001) Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ Res 88(6):630-636 (Pubitemid 32275800)
154. Yao H, Duan M, Buch S (2011) Cocaine-mediated induction of platelet-derived growth factor: implication for increased vascular permeability. Blood 117(8):2538-2547
155. Zhang ZW, Yanamoto H, Nagata I, Miyamoto S, Nakajo Y, Xue JH, Iihara K, Kikuchi H (2010) Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: proposed growth factor explanation of cerebral vasospasm. Neurosurgery 66(4):728-735
156. Zohlnhöfer D, Hausleiter J, Kastrati A, Mehilli J, Goos C, Schühlen H, Pache J, Pogatsa-Murray G, Heemann U, Dirschinger J et al (2005) A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J Am Coll Cardiol 46(11):1999-2003 (Pubitemid 41713581)